Kimmel D W, Shapiro J R, Shapiro W R
J Neurosurg. 1987 Feb;66(2):161-71. doi: 10.3171/jns.1987.66.2.0161.
In vitro drug sensitivity assays have been developed with the goal of predicting the clinical response to chemotherapy. The colony-forming assay, radiolabeled precursor inhibition assay, and microcytotoxicity assay are most commonly used. In retrospective studies, the assays correctly predict clinical response to a chemotherapeutic agent in 50% to 70% of patients and predict clinical resistance in nearly 100% of patients. All of the assays suffer from technical and theoretical problems. In vitro assays depend on cell culture and therefore do not entirely simulate in vivo conditions. Heterogeneity in chemosensitivity is commonly found and can complicate the interpretation of results. Further investigation is needed to determine if these assays will be able to select prospective chemotherapy for patients. The malignant origin of the cells in culture must be verified if meaningful conclusions are to be made.
已经开发了体外药敏试验，目的是预测化疗的临床反应。最常用的是集落形成试验、放射性标记前体抑制试验和微细胞毒性试验。在回顾性研究中，这些试验能在50%至70%的患者中正确预测对化疗药物的临床反应，并在近100%的患者中预测临床耐药性。所有这些试验都存在技术和理论问题。体外试验依赖于细胞培养，因此不能完全模拟体内条件。化疗敏感性的异质性很常见，会使结果的解释复杂化。需要进一步研究以确定这些试验是否能够为患者选择前瞻性化疗方案。如果要得出有意义的结论，必须验证培养细胞的恶性起源。
